LEHI, UTAH, USA — June 1, 2022 — Lumea Inc, a global leader in integrated digital pathology solutions, is pleased to announce the first-of-its-kind Digital Diagnostic Summit in Park City, Utah. Tempus, Verily, Myriad Genetics, AstraZeneca, and others will be presenting their latest developments in leveraging digital pathology technologies to improve patient care. Summit participants will have the opportunity to network and connect with an expert lineup of professionals discussing the practical application of the most cutting-edge digital technology.
Featured speakers include former United States Secretary of Health and Human Services, Michael Leavitt, and a number of pathologists who have made the transition to a digital pathology platform and are thriving in today’s challenging healthcare environment. Unique from academic conferences, the goal of this summit is to provide practical day-to-day advice on the benefits of making the transition to digital pathology from colleagues who have been practicing digitally for years. In addition, learn how to grow and improve your practice by deploying cutting edge technologies and network with pathologists looking to expand their practices.
“This is a rare opportunity to get first-hand experience with the latest digital pathology enabled technologies that are changing the practice of medicine and network with forward-thinking pathologists who are already practicing digitally.” John Wirthlin, CEO
The Digital Diagnostic Summit is hosted by Lumea at the beautiful St. Regis Resort in Park City, Utah. In addition to hands-on panels and sessions, all registration packages include a premiere excursion in gorgeous Park City, located at the base of the Wasatch Mountain Range.
Registration is open with limited availability. Sign up now for this one-of-a-kind opportunity to learn about the benefits of digital pathology technologies first hand. You won’t want to miss this!
Register here: DigitalDiagnosticSummit.com
Read the press release here.
Lumea is the market leader in the field of integrated digital pathology solutions. Its proprietary platform leverages new technologies to drive significant improvements in biopsy handling, tracking, workflow, and pathology sign-out. Lumea’s technology results in measurably better quality, increased efficiencies, and significant cost savings throughout the diagnostic process.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022.
Verily is a subsidiary of Alphabet that is using a data-driven, people-first approach to change the way people manage their health and the way healthcare is delivered. Launched from Google X in 2015, Verily’s purpose is to bring the promise of precision health to everyone, every day. Verily is focused on generating and activating data from a wide variety of sources, including clinical, social, behavioral and the real world, to arrive at the best solutions for a person based on a comprehensive view of the evidence. Verily uses its recognized expertise and capabilities in technology, data science and healthcare to enable the entire healthcare ecosystem to drive better health outcomes.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.